IP Library › Granted Patent US 12,508,438
Granted Patent B2
US 12,508,438 · App. 16/547,940 · Granted Dec 30, 2025

System and method for cold plasma therapy with HER-family receptors

Inventors: Xiaoqian Cheng (Falls Church, VA); Jerome Canady (Lakeland, FL)
Assignee: US Patent Innovations, LLC
A61N1/44A61B18/042A61K39/39558C07K16/32H05H2245/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,508,438
App. No.
16/547,940
Granted
Dec 30, 2025
Kind
B2
Abstract

A system and method for using a concomitant effect of cold atmospheric plasma and Trastuzumab to overcome Trastuzumab invalidity or resistance and enhances the outcome of breast cancer therapy in both HER2-positive and negative cancer cells.

Claims (11)

1 . A method for treating breast cancer comprising:

treating HER2-negative breast cancer cells with Trastuzumab at a median infective dose (ID 50 ) value for the Trastuzumab; and

treating said HER2-negative breast cancer cells with cold atmospheric plasma at a median infective dose (ID 50 ) value for the cold atmospheric plasma treatment to overcome Trastuzumab invalidity or resistance and to enhance the outcome of the Trastuzumab treatment.

2 . A method for treating breast cancer cells, comprising:

treating first samples of a breast cancer cell line with Trastuzumab at various dosages;

calculating a median infective dose (ID 50 ) value for Trastuzumab with a processor based on results of said treating first samples and storing the calculated values in an electronic storage;

treating second samples of the breast cancer cell line with cold atmospheric plasma at various settings;

calculating an ID 50 value for the cold atmospheric plasma treatment with a processor based on results of said treating second samples and storing the calculated values in an electronic storage; and

treating cancer cells concomitantly with Trastuzumab and cold atmospheric plasma at the stored ID 50 values.

3 . A method for treating breast cancer cells according to claim 2

wherein the breast cancer cells are HER2-negative cancer cells.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 051814 FRAME 0052. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 3, 2020
From: CHENG, XIAOQIAN; CANADY, JEROME, DR.
To: JEROME CANADY RESEARCH INSTITUTE FOR ADVANCED BIOLOGICAL AND TECHNICAL SCIENCES
Reel/Frame 054283/0457 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2020
From: CHENG, XIAOQIAN; CANADY, JEROME, DR.
To: US PATENT INNOVATIONS, LLC
Reel/Frame 051814/0052 →
Continuity (2)
Provisional Application 62721243 · Aug 22, 2018
Related Publication 20200069958A1 · Mar 5, 2020
References Cited (21)
US 8663643B2 · Berry et al. · 2014 [cited by applicant]
US 9999462B2 · Canady et al. · 2018 [cited by applicant]
US 10023858B2 · Canady et al. · 2018 [cited by applicant]
US 10213614B2 · Keidar et al. · 2019 [cited by applicant]
US 10329535B2 · Trink et al. · 2019 [cited by applicant]
US 10405913B2 · Canady et al. · 2019 [cited by applicant]
US 20170183631A1 · Keidar et al. · 2017 [cited by applicant]
US 20180271579A1 · Keidar et al. · 2018 [cited by applicant]
WO 2018191265A1 · 2018 [cited by applicant]
André et al., “Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.” The lancet oncology, 15(6), pp. 580-591 (Y… [cited by examiner]
Dai et al., “The Emerging Role of Gas Plasma in Oncotherapy,” Trends Biotechnology, 36(11) pp. 1183-1198, Epub Jul. 20, 2018, Accessed from the internet <doi: 10.1016/j.tibtech.2018.06.010> [retrieved on Apr. 25, 2022].… [cited by examiner]
Xu et al., “Quantitative assessment of cold atmospheric plasma anti-cancer efficacy in triple-negative breast cancers.” Plasma Processes and Polymers, 15(8):1800052 pp. 1-11 (Year: 2018). [cited by examiner]
Corsini et al., “Stroma cells: a novel target of herceptin activity.” Clinical cancer research, 9(5), pp. 1820-1825 (Year: 2003). [cited by examiner]
Kvam, E., et al., Nonthermal atmospheric plasma rapidly disinfects multidrug-resistant microbes by inducing cell surface damage. Antimicrob Agents Chemother, 2012. 56(4): p. 2028-36. [cited by applicant]
Keidar, M., Plasma for cancer treatment. Plasma Sources Science and Technology, 2015. 24(3): p. 033001. [cited by applicant]
Keidar, M., et al., Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy. Br J Cancer, 2011. 105(9): p. 1295-301. [cited by applicant]
Vu, T. and F.X. Claret, Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol, 2012. 2: p. 62. [cited by applicant]
Wang, M., et al., Cold atmospheric plasma for selectively ablating metastatic breast cancer cells. PLoS One, 2013. 8(9): p. e73741. [cited by applicant]
Kim, S.J., et al., Induction of apoptosis in human breast cancer cells by a pulsed atmospheric pressure plasma jet. Applied Physics Letters, 2010. 97(2): p. 023702. [cited by applicant]
Hudis, C.A., Trastuzumab—Mechanism of Action and Use in Clinical Practice. The New England Journal of Medicine, 2007. 357(1): p. 39-51. [cited by applicant]
Cuello, M., et al., Down-Regulation of the erbB-2 Receptor by Trastuzumab (Herceptin) Enhances Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated Apoptosis in Breast and Ovarian Cancer Cell Lines that Over… [cited by applicant]